Video

Common Health Effects of Phosphate Metabolism Disorders

Conference|ASN Kidney Week - American Society of Nephrology Kidney Week

Farzana Perwad, MD, chief of the Division of Nephrology at UCSF Benioff Children's Hospitals, discusses the common health impacts of phosphate metabolism disorders.

In a Pharmacy Times® interview, Farzana Perwad, MD, chief of the Division of Nephrology at UCSF Benioff Children's Hospitals, spoke about her 2021 ASN Kidney Week presentation on molecular insights into disorders of phosphate metabolism.

In this video, she discusses the common health impacts of phosphate metabolism disorders.

Related Videos
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com
California Wildfire, Pharmacy, Community | Image Credit: Erin | stock.adobe.com
Related Content
GLP-1, Diabetes, Type 2 Diabetes | Image Credit: © neirfy | stock.adobe.com
January 20th 2025

ASHP Midyear: Expert Discusses GLP-1 Medications and Incretin Mimetics for Diabetes Care

Ashley Gallagher, Editor
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
December 23rd 2024

Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting

Alexandra Gerlach, Associate Editor
Red blood cells, hematology -- Image credit: Rasi | stock.adobe.com
January 19th 2025

From Blinatumomab to Venetoclax: Highlights From the 66th American Society of Hematology Annual Meeting and Exposition

Douglas Braun, PharmD, RPh, CPH, CSP
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

GLP-1, Ozempic, Wegovy, Semaglutide, Diabetes, Weight Loss | Image Credit: © Peter Togel | stock.adobe.com
January 13th 2025

ASHP Midyear: Expert Discusses the GLP-1 Landscape for Diabetes Care

Ashley Gallagher, Editor
Chronic myeloid leukemia cells or CML, analyze by microscope
December 31st 2024

ASH 2024: Zanubrutinib Monotherapy, With Obinutuzimab Demonstrates Durable Efficacy and Safety in CLL/SLL

Luke Halpern, Assistant Editor